[PDF] Top 20 Quantitative Assessment of MRI Features in Patients with Relapsing-Remitting Multiple Sclerosis

... In this study twenty MRI features from 19 RRMS patients were assessed using statistical analysis. The obtained MRI features are reported in table1. According to the results, feature of ... See full document

... In multiple sclerosis (MS), a rapid onset of action in controlling clinical and MRI disease activity is an important therapeutic goal to minimize neurologic damage and irreversible accumulation of ... See full document

... the increment of activation (beta2- and gamma) in the cortex could not always be related to the performance of the cognitive task. Indeed, the BMS group showed a higher degree of cognitive impairment and the QEEG scores ... See full document

... general, patients with ≥1 relapse per year, absence of complete recovery from relapses, sustained disability progression of ≥1 and MRI progression, with or without clinical signs, are considered as ... See full document

... for patients with RRMS were as follows: 1) mild-to-moderate disability (EDSS #5) to prevent the inclusion of confounding factors; 2) the absence of corticosteroid therapy or clinical relapse for at least 1 month ... See full document

... the MRI part of the study, UNRELATED: Board Membership: Biogen Idec, Merck, Teva, Novartis, Consultancy: Gen- zyme, Bayer, Grants/Grants Pending: Biogen Idec,* Novartis,* Payment for Lectures (including service on ... See full document

... many patients in the treatment arm dropped out, most patients tolerated methylprednisolone as an add-on to interferon ...in patients with breakthrough disease who are on interferon beta ...of ... See full document

... Fingolimod (FTY720) - Gilenya® is an oral immuno- modulatory drug that serves as a functional antagonist of the sphinosine-1-phosphate (S1P) receptor family resulting in lymphocyte sequestration within lymph nodes [15, ... See full document

... treat relapsing-remitting multiple sclerosis (RRMS) are expanding as newer, and more potent, disease-modifying treatments become ...have multiple effects on the immune system, including ... See full document

... Patient-reported outcomes have been de fi ned as outcomes obtained “ directly from the patient, without interpretation of the patient ’ s response by a clinician or anyone else, ” 7 and are typically obtained through ... See full document

... for relapsing-remitting multiple sclerosis, namely glatiramer acetate and the β- interferons, provide a marked reduction in relapse rates and in MRI markers of disease activity ... See full document

... Multiple sclerosis (MS) is a chronic autoimmune-mediated demyelinating disease of the central nervous system (CNS) that is usually associated with varying degrees of progressive ...most patients the ... See full document

... of patients with psoriasis, and undoubtedly quali- fies the drug for long-term ...of patients initially experi- ence diarrhea and up to 30% experience ...by patients with relapsing forms of MS ... See full document

... Abstract: Multiple sclerosis (MS) is a debilitating neurological disorder that affects nearly 2 million adults, mostly in the prime of their youth. An environmental trigger, such as a viral infection, is ... See full document

... and quantitative signal intensity changes in the brain on baseline precontrast T1-weighted MRI data of a pediatric patient who received 35 MRI examinations with gadolinium-based contrast agent (GBCA) ... See full document

... of patients with enhancing ...some relapsing-remit- ting diseases progress to chronic-progressive disease (44), which may have implications for therapeutic ...of patients who have significant ELV in ... See full document

... All samples were tested for HCV Antibody (Ab). The Ab to HCV was determined by ELISA method using commercial kit (Pishtaz, Iran). Liver enzymes [Alkalin Phosphatase (ALP), Alanine aminotransferase (ALT) and Aspartate ... See full document

... eters, patients’ personal factors, risk tolerance, and the ability to adhere to stringent monitoring requirements have to be considered before treatment ... See full document

... all patients underwent CSF and blood tests, complete neurological evaluation, and brain (and in selected cases also spinal) MRI ...recent assessment of dis- ... See full document

... for patients to prevent or abrogate ongoing joint ...eRA patients (n = 34) using the Alu115 and b-actin205 primer sets and performed additional analyses with mate- rial from healthy controls (n = ...esRA ... See full document